Truist Securities analyst Robyn Karnauskas maintains Gilead Sciences (NASDAQ:GILD) with a Hold and raises the price target from $71 to $76.
Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts on weight and long-term metabolic profile over 52 weeks of treatment.
